At VIVA Wellness, we combine evidence-based GLP-1 weight loss treatment with provider-led care, integrated wellness services, and a level of personal attention that national telehealth platforms cannot replicate
A novel cardiometabolic therapeutic prospect Cardiometabolic diseases as diabetes mellitus, heart disease, overweight, obesity, hypertension, hyperlipidemia and its multiple macro and microvascular complications (ischemic cardiomyopathy, stroke, chronic kidney disease, retinopathy, peripheral neuropathy, etc.) are conditions closely related to each other and constitute at present time the leading cause of morbility, disability and death in the world [28]
If you drink it, go easy on cream and sugar liquid calories add up fast
Therefore, several classes of drugs, such as alpha-glucosidase inhibitors (AGI), amylinomimetics, biguanides, bile acid sequestrants, dopaminergic antagonists, DPP4 inhibitors (DPP4i), insulin and insulin secretagogues (IS), sulfonylureas, meglitinides, sodium-glucose cotransporter-2 inhibitor (SGLT2i), and thiazolidinediones (TZDs), including the glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been made available for the management of T2DM (Tahrani et al., 2016
